🇺🇸 FDA
Pipeline program

Ponatinib

Ponatinib-3001

Phase 3 small_molecule active

Quick answer

Ponatinib for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials